<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36868585</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000864</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000864</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Studies show that generic cardiovascular risk (CVR) prediction tools may underestimate CVR in SLE. We examined, for the first time to our knowledge, whether generic and disease-adapted CVR scores may predict subclinical atherosclerosis progression in SLE.</AbstractText><AbstractText Label="METHODS">We included all eligible patients with SLE without a history of cardiovascular events or diabetes mellitus, who had a 3-year carotid and femoral ultrasound follow-up examination. Five generic (Systematic Coronary Risk Evaluation (SCORE), Framingham Risk Score (FRS), Pooled Cohort Risk Equation, Globorisk, Prospective Cardiovascular M&#xfc;nster) and three 'SLE-adapted' CVR scores (modified Systematic Coronary Risk Evaluation (mSCORE), modified Framingham Risk Score (mFRS), QRESEARCH Risk Estimator V.3 (QRISK3)) were calculated at baseline. The performance of CVR scores to predict atherosclerosis progression (defined as new atherosclerotic plaque development) was tested with Brier Score (BS), area under the receiver operating characteristic curve (AUROC) and Matthews correlation coefficient (MCC), while rank correlation was tested with Harrell's <i>c</i>-index. Binary logistic regression was also applied to examine determinants of subclinical atherosclerosis progression.</AbstractText><AbstractText Label="RESULTS">Twenty-six (21%) of 124 included patients (90% female, mean age 44.4&#xb1;11.7 years) developed new atherosclerotic plaques after a mean of 39.7&#xb1;3.8 months' follow-up period. Performance analysis showed that plaque progression was better predicted by the mFRS (BS 0.14, AUROC 0.80, MCC 0.22) and QRISK3 (BS 0.16, AUROC 0.75, MCC 0.25). <i>c</i>-Index showed no superiority for discrimination between mFRS and QRISK3. In the multivariate analysis, QRISK3 (OR 4.24, 95% CI 1.30 to 13.78, p=0.016) among the CVR prediction scores and age (OR 1.13, 95% CI 1.06 to 1.21, p&lt;0.001), cumulative glucocorticoid dose (OR 1.04, 95% CI 1.01 to 1.07, p=0.010) and antiphospholipid antibodies (OR 3.66, 95% CI 1.24 to 10.80, p=0.019) among disease-related CVR factors were independently associated with plaque progression.</AbstractText><AbstractText Label="CONCLUSIONS">Application of SLE-adapted CVR scores such as QRISK3 or mFRS, as well as monitoring for glucocorticoid exposure and the presence of antiphospholipid antibodies, can help to improve CVR assessment and management in SLE.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panopoulos</LastName><ForeName>Stylianos</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drosos</LastName><ForeName>George C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Cardiovascular Risk Research Laboratory, First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantonis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiovascular Risk Research Laboratory, First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sfikakis</LastName><ForeName>Petros P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Risk Research Laboratory, First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tektonidou</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0003-2238-0975</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece mtektonidou@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Risk Research Laboratory, First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082742" MajorTopicYN="N">Heart Disease Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058226" MajorTopicYN="Y">Plaque, Atherosclerotic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atherosclerosis</Keyword><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">ultrasonography</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36868585</ArticleId><ArticleId IdType="pmc">PMC9990693</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000864</ArticleId><ArticleId IdType="pii">10/1/e000864</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tektonidou MG, Lewandowski LB, Hu J, et al. . Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 2017;76:2009&#x2013;16. 10.1136/annrheumdis-2017-211663</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211663</ArticleId><ArticleId IdType="pubmed">28794077</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza DCC, Santo AH, Sato EI. Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. J Rheumatol 2012;39:496&#x2013;503. 10.3899/jrheum.110241</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.110241</ArticleId><ArticleId IdType="pubmed">22247362</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Wang Z, Ward MM. Brief report: trends in hospitalizations due to acute coronary syndromes and stroke in patients with systemic lupus erythematosus, 1996 to 2012. Arthritis Rheumatol 2016;68:2680&#x2013;5. 10.1002/art.39758</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39758</ArticleId><ArticleId IdType="pmc">PMC5083218</ArticleId><ArticleId IdType="pubmed">27273732</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya M, Feldman CH, Chen SK, et al. . Comparative risks of cardiovascular disease in patients with systemic lupus erythematosus, diabetes mellitus, and in general Medicaid recipients. Arthritis Care Res (Hoboken) 2020;72:1431&#x2013;9. 10.1002/acr.24328</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24328</ArticleId><ArticleId IdType="pmc">PMC7781242</ArticleId><ArticleId IdType="pubmed">32475049</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzi S, Meilahn EN, Rairie JE, et al. . Age-Specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:408&#x2013;15. 10.1093/oxfordjournals.aje.a009122</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a009122</ArticleId><ArticleId IdType="pubmed">9048514</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdany J, Pooley N, Langham J, et al. . Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open 2020;6. 10.1136/rmdopen-2020-001247</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001247</ArticleId><ArticleId IdType="pmc">PMC7722272</ArticleId><ArticleId IdType="pubmed">32900883</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford) 2020;59:V29&#x2013;38. 10.1093/rheumatology/keaa382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa382</ArticleId><ArticleId IdType="pmc">PMC7719040</ArticleId><ArticleId IdType="pubmed">33280012</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepoli MF, Hoes AW, Agewall S, et al. . 2016 european guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the european association for cardiovascular prevention &amp; rehabilitation (EACPR). Eur Heart J 2016;37:2315&#x2013;81. 10.1093/eurheartj/ehw106</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw106</ArticleId><ArticleId IdType="pmc">PMC4986030</ArticleId><ArticleId IdType="pubmed">27222591</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G-C, Liu H-R, Leng R-X, et al. . Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis. Autoimmun Rev 2016;15:22&#x2013;37. 10.1016/j.autrev.2015.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.10.002</ArticleId><ArticleId IdType="pubmed">26455562</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrot P, Foret J, Barnetche T, et al. . Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. Joint Bone Spine 2018;85:155&#x2013;63. 10.1016/j.jbspin.2017.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2017.12.009</ArticleId><ArticleId IdType="pubmed">29288864</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman MJ, Shanker B-A, Davis A, et al. . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399&#x2013;406. 10.1056/NEJMoa035471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa035471</ArticleId><ArticleId IdType="pubmed">14681505</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Kravvariti E, Konstantonis G, et al. . Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis. Autoimmunity Reviews 2017;16:308&#x2013;12. 10.1016/j.autrev.2017.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.01.009</ArticleId><ArticleId IdType="pubmed">28147263</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosos GC, Vedder D, Houben E, et al. . EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2022;81:768&#x2013;79. 10.1136/annrheumdis-2021-221733</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221733</ArticleId><ArticleId IdType="pubmed">35110331</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaco K, Ocampo V, Ayala AP, et al. . Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: a systematic review. J Rheumatol 2020;47:928&#x2013;38. 10.3899/jrheum.190261</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.190261</ArticleId><ArticleId IdType="pubmed">31416923</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafri K, Ogdie A, Qasim A, et al. . Discordance of the Framingham cardiovascular risk score and the 2013 American College of cardiology/american heart association risk score in systemic lupus erythematosus and rheumatoid arthritis. Clin Rheumatol 2018;37:467&#x2013;74. 10.1007/s10067-017-3860-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-017-3860-x</ArticleId><ArticleId IdType="pmc">PMC5908810</ArticleId><ArticleId IdType="pubmed">28993952</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivakumaran J, Harvey P, Omar A, et al. . Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med 2021;8:e000448. 10.1136/lupus-2020-000448</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000448</ArticleId><ArticleId IdType="pmc">PMC8162102</ArticleId><ArticleId IdType="pubmed">34045359</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosos GC, Konstantonis G, Sfikakis PP, et al. . Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. Eur J Prev Cardiol 2020:204748732090665. 10.1177/2047487320906650</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487320906650</ArticleId><ArticleId IdType="pubmed">32122200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CP, Oeser A, Avalos I, et al. . Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006;15:562&#x2013;9. 10.1177/0961203306071870</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306071870</ArticleId><ArticleId IdType="pubmed">17080910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Singh M, Lele S, et al. . Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus. Lupus Sci Med 2022;9:e000564. 10.1136/lupus-2021-000564</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000564</ArticleId><ArticleId IdType="pmc">PMC8867320</ArticleId><ArticleId IdType="pubmed">35193947</ArticleId></ArticleIdList></Reference><Reference><Citation>R.H. Raiko J, Magnussen CG, Kivim&#xe4;ki M, et al. . Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young finns study. European Journal of Cardiovascular Prevention &amp; Rehabilitation 2010;17:549&#x2013;55. 10.1097/HJR.0b013e3283386419</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJR.0b013e3283386419</ArticleId><ArticleId IdType="pmc">PMC2907448</ArticleId><ArticleId IdType="pubmed">20354441</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFilippis AP, Blaha MJ, Ndumele CE, et al. . The association of Framingham and reynolds risk scores with incidence and progression of coronary artery calcification in MESA (multi-ethnic study of atherosclerosis). Journal of the American College of Cardiology 2011;58:2076&#x2013;83. 10.1016/j.jacc.2011.08.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.08.022</ArticleId><ArticleId IdType="pmc">PMC4079464</ArticleId><ArticleId IdType="pubmed">22051329</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitu O, Crisan A, Redwood S, et al. . The relationship between cardiovascular risk scores and several markers of subclinical atherosclerosis in an asymptomatic population. JCM 2021;10:955. 10.3390/jcm10050955</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10050955</ArticleId><ArticleId IdType="pmc">PMC7957548</ArticleId><ArticleId IdType="pubmed">33804436</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis &amp; Rheumatism 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006;4:295&#x2013;306. 10.1111/j.1538-7836.2006.01753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman MJ, Naqvi TZ, Gardin JM, et al. . Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of echocardiography and the Society of vascular medicine and biology. Journal of the American Society of Echocardiography 2006;19:943&#x2013;54. 10.1016/j.echo.2006.04.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2006.04.020</ArticleId><ArticleId IdType="pubmed">16880089</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy RM, Py&#xf6;r&#xe4;l&#xe4; K, Fitzgerald AP, et al. . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the score project. European Heart Journal 2003;24:987&#x2013;1003. 10.1016/S0195-668X(03)00114-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0195-668X(03)00114-3</ArticleId><ArticleId IdType="pubmed">12788299</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino RB, Vasan RS, Pencina MJ, et al. . General cardiovascular risk profile for use in primary care. Circulation 2008;117:743&#x2013;53. 10.1161/CIRCULATIONAHA.107.699579</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.699579</ArticleId><ArticleId IdType="pubmed">18212285</ArticleId></ArticleIdList></Reference><Reference><Citation>Goff DC, Lloyd-Jones DM, Bennett G, et al. . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S49&#x2013;73. 10.1161/01.cir.0000437741.48606.98</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.0000437741.48606.98</ArticleId><ArticleId IdType="pubmed">24222018</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajifathalian K, Ueda P, Lu Y, et al. . A novel risk score to predict cardiovascular disease risk in national populations (globorisk): a pooled analysis of prospective cohorts and health examination surveys. The Lancet Diabetes &amp; Endocrinology 2015;3:339&#x2013;55. 10.1016/S2213-8587(15)00081-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(15)00081-9</ArticleId><ArticleId IdType="pubmed">25819778</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular m&#xfc;nster (PROCAM) study. Circulation 2002;105:310&#x2013;5. 10.1161/hc0302.102575</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hc0302.102575</ArticleId><ArticleId IdType="pubmed">11804985</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz MB, Iba&#xf1;ez D, Su J, et al. . Modified Framingham risk factor score for systemic lupus erythematosus. J Rheumatol 2016;43:875&#x2013;9. 10.3899/jrheum.150983</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.150983</ArticleId><ArticleId IdType="pubmed">26879352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099. 10.1136/bmj.j2099</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j2099</ArticleId><ArticleId IdType="pmc">PMC5441081</ArticleId><ArticleId IdType="pubmed">28536104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessant R, Duncan R, Ambler G, et al. . Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case&#x2013;control study. Arthritis Rheum 2006;55:892&#x2013;9. 10.1002/art.22343</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22343</ArticleId><ArticleId IdType="pubmed">17139666</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri MA, Barr E, Magder LS. Development of a systemic lupus erythematosus cardiovascular risk equation. Lupus Sci Med 2019;6:e000346. 10.1136/lupus-2019-000346</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000346</ArticleId><ArticleId IdType="pmc">PMC6827738</ArticleId><ArticleId IdType="pubmed">31749976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballocca F, D&#x2019;Ascenzo F, Moretti C, et al. . Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiolog 2015;22:1435&#x2013;41. 10.1177/2047487314546826</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487314546826</ArticleId><ArticleId IdType="pubmed">25139772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooter AJ, Kostense PJ, Groenewold J, et al. . Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. Circulation 2011;124:741&#x2013;5. 10.1161/CIRCULATIONAHA.111.035725</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.035725</ArticleId><ArticleId IdType="pubmed">21824935</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Del Mercado M, Perez-Vazquez F de J, Gomez-Ba&#xf1;uelos E, et al. . Subclinical parameters of arterial stiffness and arteriosclerosis correlate with QRISK3 in systemic lupus erythematosus. PLoS One 2018;13:e0207520. 10.1371/journal.pone.0207520</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0207520</ArticleId><ArticleId IdType="pmc">PMC6281193</ArticleId><ArticleId IdType="pubmed">30517121</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards N, Langford-Smith AWW, Parker BJ, et al. . QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. Lupus Sci Med 2018;5:e000272. 10.1136/lupus-2018-000272</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000272</ArticleId><ArticleId IdType="pmc">PMC6109811</ArticleId><ArticleId IdType="pubmed">30167314</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevedo-Abeledo JC, Caceres L, Palazuelos C, et al. . QRISK3 relation to carotid plaque is higer than that of score in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2022;61:1408&#x2013;16. 10.1093/rheumatology/keab531</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab531</ArticleId><ArticleId IdType="pubmed">34240117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kravvariti E, Konstantonis G, Sfikakis PP, et al. . Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. Rheumatology (Oxford) 2018;57:2158&#x2013;66. 10.1093/rheumatology/key233</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key233</ArticleId><ArticleId IdType="pubmed">30102390</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno MND, Emmi G, Ambrosino P, et al. . Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: a cross-sectional study. International Journal of Cardiology 2019;274:1&#x2013;6. 10.1016/j.ijcard.2018.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2018.06.010</ArticleId><ArticleId IdType="pubmed">30454720</ArticleId></ArticleIdList></Reference><Reference><Citation>Majka DS, Liu K, Pope RM, et al. . Antiphospholipid antibodies and sub-clinical atherosclerosis in the coronary artery risk development in young adults (cardia) cohort. Inflamm Res 2013;62:919&#x2013;27. 10.1007/s00011-013-0652-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-013-0652-x</ArticleId><ArticleId IdType="pmc">PMC4122510</ArticleId><ArticleId IdType="pubmed">23959159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Mak A, Leong J, et al. . Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med 2021;8:e000590. 10.1136/lupus-2021-000590</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000590</ArticleId><ArticleId IdType="pmc">PMC8689160</ArticleId><ArticleId IdType="pubmed">34930819</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Andreoli L, Limper M, et al. . EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296&#x2013;304. 10.1136/annrheumdis-2019-215213</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215213</ArticleId><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun EY, Alvarez C, Sheikh SZ. Association of lupus nephritis with coronary artery disease by ISN/RPS classification: results from a large real&#x2010;world lupus population. ACR Open Rheuma 2019;1:244&#x2013;50. 10.1002/acr2.1035</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.1035</ArticleId><ArticleId IdType="pmc">PMC6858008</ArticleId><ArticleId IdType="pubmed">31777800</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, et al. . Excess atherosclerosis in systemic lupus erythematosus, -A matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls. PLoS One 2017;12:e0174572. 10.1371/journal.pone.0174572</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174572</ArticleId><ArticleId IdType="pmc">PMC5393555</ArticleId><ArticleId IdType="pubmed">28414714</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Laskari K, Panagiotakos DB, et al. . Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009;61:29&#x2013;36. 10.1002/art.24232</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24232</ArticleId><ArticleId IdType="pubmed">19116963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte A, Garcia de Bustos A, Ruiz-Arruza I, et al. . Anti-Phospholipid antibodies do not predict damage in SLE patients in the 21st century-an observational study from the lupus-cruces cohort. Rheumatology (Oxford) 2021;61:249&#x2013;57. 10.1093/rheumatology/keab307</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab307</ArticleId><ArticleId IdType="pubmed">33769455</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira CB, Kaplan MJ. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. Semin Immunopathol 2022;44:309&#x2013;24. 10.1007/s00281-022-00922-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-022-00922-y</ArticleId><ArticleId IdType="pmc">PMC9064999</ArticleId><ArticleId IdType="pubmed">35355124</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman MJ, Crow MK, Lockshin MD, et al. . Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56:3412&#x2013;9. 10.1002/art.22924</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22924</ArticleId><ArticleId IdType="pubmed">17907140</ArticleId></ArticleIdList></Reference><Reference><Citation>Telles RW, Lanna CCD, Sousa AJ, et al. . Progression of carotid atherosclerosis in patients with systemic lupus erythematosus. Clin Rheumatol 2013;32:1293&#x2013;300. 10.1007/s10067-013-2264-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-013-2264-9</ArticleId><ArticleId IdType="pubmed">23620348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiani AN, Post WS, Magder LS, et al. . Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford) 2011;50:2071&#x2013;9. 10.1093/rheumatology/ker285</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker285</ArticleId><ArticleId IdType="pmc">PMC3247795</ArticleId><ArticleId IdType="pubmed">21875880</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldan PC, Greene ER, Qualls CR, et al. . Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus. Rheumatol Int 2019;39:1027&#x2013;36. 10.1007/s00296-019-04267-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04267-y</ArticleId><ArticleId IdType="pubmed">30877372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakshi J, Croca SC, Griffin M, et al. . Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus. Rheumatology 2022;62:225&#x2013;33. 10.1093/rheumatology/keac259</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac259</ArticleId><ArticleId IdType="pmc">PMC9788823</ArticleId><ArticleId IdType="pubmed">35482484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>